These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8584685)

  • 41. Long-term haloperidol treatment (but not risperidone) enhances addiction-related behaviors in mice: role of dopamine D2 receptors.
    Carvalho RC; Fukushiro DF; Helfer DC; Callegaro-Filho D; Trombin TF; Zanlorenci LH; Sanday L; Silva RH; Frussa-Filho R
    Addict Biol; 2009 Jul; 14(3):283-93. PubMed ID: 19298320
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effect of chronic treatment with a novel aryl-piperazine antipsychotic on monoamine receptors in rat brain.
    Shapiro LA; Offord SJ; Ordway GA
    Brain Res; 1995 Apr; 677(2):250-6. PubMed ID: 7552250
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Pharmacological characteristics of perospirone hydrochloride, a novel antipsychotic agent].
    Ohno Y
    Nihon Yakurigaku Zasshi; 2000 Oct; 116(4):225-31. PubMed ID: 11084919
    [TBL] [Abstract][Full Text] [Related]  

  • 44. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
    Millan MJ; Gobert A; Newman-Tancredi A; Audinot V; Lejeune F; Rivet JM; Cussac D; Nicolas JP; Muller O; Lavielle G
    J Pharmacol Exp Ther; 1998 Sep; 286(3):1341-55. PubMed ID: 9732398
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Carbamazepine reduces dopamine-mediated behavior in chronic neuroleptic-treated and untreated rats: implications for treatment of tardive dyskinesia and hyperdopaminergic states.
    LaHoste GJ; Wigal T; King BH; Schuck SEB; Crinella FM; Swanson JM
    Exp Clin Psychopharmacol; 2000 Feb; 8(1):125-132. PubMed ID: 10743913
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dopamine D2(High) receptors moderately elevated by sertindole.
    Seeman P
    Synapse; 2008 May; 62(5):389-93. PubMed ID: 18293356
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist.
    Reavill C; Kettle A; Holland V; Riley G; Blackburn TP
    Br J Pharmacol; 1999 Feb; 126(3):572-4. PubMed ID: 10188965
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Chronic haloperidol treatment leads to an increase in the intramembrane interaction between adenosine A2 and dopamine D2 receptors in the neostriatum.
    Ferré S; Schwarcz R; Li XM; Snaprud P; Ogren SO; Fuxe K
    Psychopharmacology (Berl); 1994 Nov; 116(3):279-84. PubMed ID: 7892417
    [TBL] [Abstract][Full Text] [Related]  

  • 49. 5-HT2 receptor blockade by ICI 169,369 and other 5-HT2 antagonists modulates the effects of D-2 dopamine receptor blockade.
    Saller CF; Czupryna MJ; Salama AI
    J Pharmacol Exp Ther; 1990 Jun; 253(3):1162-70. PubMed ID: 2141636
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A comparison of the effects of risperidone, raclopride, and ritanserin on intravenous self-administration of d-amphetamine.
    Fletcher PJ
    Pharmacol Biochem Behav; 1998 May; 60(1):55-60. PubMed ID: 9610924
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Enhancement of antipsychoticlike properties of raclopride in rats using the selective serotonin2A receptor antagonist MDL 100,907.
    Wadenberg ML; Hicks PB; Richter JT; Young KA
    Biol Psychiatry; 1998 Sep; 44(6):508-15. PubMed ID: 9777184
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chronic treatment with clozapine or haloperidol differentially regulates dopamine and serotonin receptors in rat brain.
    O'Dell SJ; La Hoste GJ; Widmark CB; Shapiro RM; Potkin SG; Marshall JF
    Synapse; 1990; 6(2):146-53. PubMed ID: 2237777
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Risperidone inhibits 5-hydroxytryptaminergic neuronal activity in the dorsal raphe nucleus by local release of 5-hydroxytryptamine.
    Hertel P; Nomikos GG; Svensson TH
    Br J Pharmacol; 1997 Dec; 122(8):1639-46. PubMed ID: 9422809
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Regulation of ionotropic glutamate receptors following subchronic and chronic treatment with typical and atypical antipsychotics.
    Tarazi FI; Florijn WJ; Creese I
    Psychopharmacology (Berl); 1996 Dec; 128(4):371-9. PubMed ID: 8986008
    [TBL] [Abstract][Full Text] [Related]  

  • 55. 5-HT1A and 5-HT7 receptors contribute to lurasidone-induced dopamine efflux.
    Huang M; Horiguchi M; Felix AR; Meltzer HY
    Neuroreport; 2012 May; 23(7):436-40. PubMed ID: 22415605
    [TBL] [Abstract][Full Text] [Related]  

  • 56. 5-HT1A receptor agonist properties of the antipsychotic, nemonapride: comparison with bromerguride and clozapine.
    Assié MB; Cosi C; Koek W
    Eur J Pharmacol; 1997 Sep; 334(2-3):141-7. PubMed ID: 9369342
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combined serotonin (5-HT)1A agonism, 5-HT(2A) and dopamine D₂ receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats.
    Oyamada Y; Horiguchi M; Rajagopal L; Miyauchi M; Meltzer HY
    Behav Brain Res; 2015 May; 285():165-75. PubMed ID: 25448429
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Differential effect of subchronic treatment with various neuroleptic agents on serotonin2 receptors in rat cerebral cortex.
    Andree TH; Mikuni M; Tong CY; Koenig JI; Meltzer HY
    J Neurochem; 1986 Jan; 46(1):191-7. PubMed ID: 2866233
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity.
    Ishibashi T; Horisawa T; Tokuda K; Ishiyama T; Ogasa M; Tagashira R; Matsumoto K; Nishikawa H; Ueda Y; Toma S; Oki H; Tanno N; Saji I; Ito A; Ohno Y; Nakamura M
    J Pharmacol Exp Ther; 2010 Jul; 334(1):171-81. PubMed ID: 20404009
    [TBL] [Abstract][Full Text] [Related]  

  • 60. 5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex.
    Rollema H; Lu Y; Schmidt AW; Sprouse JS; Zorn SH
    Biol Psychiatry; 2000 Aug; 48(3):229-37. PubMed ID: 10924666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.